Avinger Inc. (AVGR)

1.11
NASDAQ : Health Technology
Prev Close 0.91
Day Low/High 0.85 / 1.15
52 Wk Low/High 0.77 / 12.60
Avg Volume 371.10K
Exchange NASDAQ
Shares Outstanding 10.24M
Market Cap 9.32M
EPS -33.40
P/E Ratio 0.06
Div & Yield N.A. (N.A)

Latest News

Avinger Announces Proposed Underwritten Public Offering Of Common Stock

Avinger Announces Proposed Underwritten Public Offering Of Common Stock

REDWOOD CITY, Calif., Aug.

Avinger Announces Pantheris SV Limited Launch And Successful Treatment Of First Patients In The United States

Avinger Announces Pantheris SV Limited Launch And Successful Treatment Of First Patients In The United States

REDWOOD CITY, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc.

Avinger To Announce Second Quarter 2019 Financial Results On July 31, 2019

Avinger To Announce Second Quarter 2019 Financial Results On July 31, 2019

REDWOOD CITY, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc.

Avinger Announces First-in-Patient Use Of Extended Nosecone Version Of Next Generation Pantheris

Avinger Announces First-in-Patient Use Of Extended Nosecone Version Of Next Generation Pantheris

Three patients successfully treated using next generation image-guided atherectomy device with enhanced tissue removal capacity for treatment of peripheral artery disease

Avinger Provides Update On U.S. Intellectual Property Portfolio

Avinger Provides Update On U.S. Intellectual Property Portfolio

Three New Patents Allowed or Issued for Proprietary CTO Crossing Devices

OPS Code Established For Peripheral Vascular OCT Imaging In Germany

OPS Code Established For Peripheral Vascular OCT Imaging In Germany

New Code is a Potential Precursor to Higher Reimbursement Levels in German DRG System

Avinger Announces Closing Of $18 Million Underwritten Public Offering

Avinger Announces Closing Of $18 Million Underwritten Public Offering

Secured Lenders Convert $38 Million of Debt into Equity

Avinger Announces Pricing Of $18 Million Underwritten Public Offering

Avinger Announces Pricing Of $18 Million Underwritten Public Offering

Secured Lenders Convert $38 Million of Debt into Equity

Avinger's Next Generation Pantheris Featured In Live Case Transmission At Leipzig Interventional Course 2018

Avinger's Next Generation Pantheris Featured In Live Case Transmission At Leipzig Interventional Course 2018

Leipzig Interventional Course is a leading global forum for new methods and technology in the field of vascular medicine

Avinger Announces Reverse Stock Split

Avinger Announces Reverse Stock Split

Avinger Announces Treatment Of First Patients Globally With Next Generation Pantheris

Avinger Announces Treatment Of First Patients Globally With Next Generation Pantheris

Seven patients successfully treated using next generation image-guided atherectomy device for treatment of peripheral artery disease

Avinger Receives CE Marking Approval For Next Generation Pantheris Image-Guided Atherectomy Device

Avinger Receives CE Marking Approval For Next Generation Pantheris Image-Guided Atherectomy Device

Features included in next generation device represent an important advance in the Pantheris Lumivascular System used for treatment of peripheral artery disease

Avinger Announces Change In Board Leadership

Avinger Announces Change In Board Leadership

Dr. John B. Simpson Departs Company; James G. Cullen Appointed Non-executive Chairman

Avinger Receives 510(k) Clearance For Design Modifications To Enhance Performance Of Pantheris Image-Guided Atherectomy Device

Avinger Receives 510(k) Clearance For Design Modifications To Enhance Performance Of Pantheris Image-Guided Atherectomy Device

Updates to First-Ever Image-Guided Atherectomy Device Designed to Improve Efficiency, Reliability, and Ease of Use for Physicians

Avinger Announces First Patient Enrolled In Its IDE Study Of The Pantheris Image-Guided Atherectomy System For Treatment Of In-Stent Restenosis

Avinger Announces First Patient Enrolled In Its IDE Study Of The Pantheris Image-Guided Atherectomy System For Treatment Of In-Stent Restenosis

INSIGHT Clinical Trial to Evaluate Safety and Effectiveness of Pantheris Image-Guided Atherectomy to Treat In-Stent Restenosis in Lower Extremity Arteries

Avinger Receives CE Marking Approval For In-Stent Restenosis Treatment Indication With Pantheris Image-Guided Atherectomy

Avinger Receives CE Marking Approval For In-Stent Restenosis Treatment Indication With Pantheris Image-Guided Atherectomy

Pantheris Image-Guided Atherectomy Device Designed to Empower Physicians to Precisely Treat Peripheral Artery Disease

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of Upcoming September 5th Deadline For Lead Plaintiff Motions In Securities Class Action Against Avinger, Inc. (AVGR)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of Upcoming September 5th Deadline For Lead Plaintiff Motions In Securities Class Action Against Avinger, Inc. (AVGR)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that September 5, 2017, is the deadline to file motions to be the lead plaintiff in...

AVINGER LOSS NOTICE: Rosen Law Firm Reminds Avinger, Inc. Investors Of Important Deadline In Class Action

AVINGER LOSS NOTICE: Rosen Law Firm Reminds Avinger, Inc. Investors Of Important Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Avinger, Inc.

TheStreet Quant Rating: D (Sell)